Pharmacokinetics of teicoplanin in an ICU population of children and infants

dc.contributor.author	Λουκάς, Ιωάννης	el
dc.contributor.author	Καρίκας, Γεώργιος-Αλβέρτος	el
dc.contributor.author	Γαζούλη, Μαρία	el
dc.contributor.author	Καλαμπαλίκης, Παναγιώτης	el
dc.contributor.author	Χατζής, Τάσος	el
dc.date.accessioned	2015-05-08T22:04:04Z
dc.date.available	2015-05-08T22:04:04Z
dc.date.issued	2015-05-09
dc.identifier.uri	http://hdl.handle.net/11400/10015
dc.rights	Αναφορά Δημιουργού-Μη Εμπορική Χρήση-Όχι Παράγωγα Έργα 3.0 Ηνωμένες Πολιτείες	*
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/3.0/us/	*
dc.source	http://link.springer.com/article/10.1023%2FB%3APHAM.0000048198.56873.d8	en
dc.subject	βρέφη
dc.subject	φαρμακοκινητική
dc.subject	προσομοίωση
dc.subject	τειχοπλανινο
dc.subject	infants
dc.subject	Pharmacokinetics
dc.subject	simulation
dc.subject	teicoplanin
dc.title	Pharmacokinetics of teicoplanin in an ICU population of children and infants	en
heal.type	journalArticle
heal.classification	Φαρμακευτική
heal.classification	Παιδιά
heal.classification	Pharmacy
heal.classification	Children
heal.classificationURI	N/A-Φαρμακευτική
heal.classificationURI	N/A-Παιδιά
heal.classificationURI	http://id.loc.gov/authorities/subjects/sh85100603
heal.classificationURI	http://id.loc.gov/authorities/subjects/sh85023418
heal.keywordURI	http://id.loc.gov/authorities/subjects/sh00006940
heal.contributorName	Μαχαίρας, Παναγιώτης	el
heal.identifier.secondary	ISSN: 1573-904X
heal.language	en
heal.access	campus
heal.recordProvider	Τεχνολογικό Εκπαιδευτικό Ίδρυμα Αθήνας. Σχολή Επαγγελμάτων Υγείας και Πρόνοιας. Τμήμα Ιατρικών Εργαστηρίων	el
heal.publicationDate	2004-11
heal.bibliographicCitation	Lukas, J.C., Karikas, G., Gazouli, M., Kalabalikis, P., Hatzis, T. et al. (2004) Pharmacokinetics of teicoplanin in an ICU population of children and infants. Pharmaceutical Research. [Online] 21 (11). pp.2064-2071. Available from: http://link.springer.com [Accessed 08/05/2015]	en
heal.abstract	Purpose. Better dosing is needed for antibiotics, including teicoplanin (TEI), to prevent emergence of resistant bacterial strains. Here, we assess the TEI pharmacokinetics (PK) related to a 10 mg/l minimum inhibitory concentration (MIC) target in ICU children (4 to 120 months; n = 20) with gram+ infections. Methods. Standard administration of TEI was with three 10 mg/kg Q12h, loading infusions, and maintainance with 10 mg/kg or 15 mg/kg Q24h. During maintenance, 9 samples (3/day) were collected per patient and the PK analyzed with Nonlinear Mixed Effects Model (NONMEM). Results. Thirty-five percent of concentrations in older children (≥2 months) vs. 8% in younger infants (<12 months) were below the target MIC. The global bicompartmental population PK parameters were [mean (interindividual CV%)] CL = 0.23 l/h [72%], V = 3.16 l [58%], k12 = 0.23 h−1, and k21 = 0.04 h−1. Two PK subpopulations were identified. The older children had CL = 0.29 [23%] l/h, V = 3.9 l and the younger infants, CL = 0.09 [37%] l/h, V = 1.05 l. Residual error was reduced from 52% to around 30% in the final models. Conclusions. Older children in the ICU may require relatively higher doses of teicoplanin. However, a study in a larger population is needed.	en
heal.journalName	Pharmaceutical Research	en
heal.journalType	peer-reviewed
heal.fullTextAvailability	true